BioCentury
ARTICLE | Company News

Cellmid, Advangen deal

May 13, 2013 7:00 AM UTC

Cellmid acquired Advangen for ¥120 million ($1.2 million) in cash and 55.7 million shares valued at A$1.7 million ($1.7 million) based on Cellmid's close of A$0.03 on May 7, the day before the deal wa...